|
Characteristics of the breast cancer case – control sample in the European Prospective into Cancer-Norfolk cohort |
|||
| Cases (n = 237) |
Controls (n = 952) |
P valuea |
|
|
|
|||
| Age (years) |
58.5 (8.6) |
58.7 (8.9) |
0.791 |
| Weight (kg) |
69.2 (11.4) |
67.7 (11.2) |
0.068 |
| Energy intake (kcal/day) |
1745.9 (386.6) |
1678.6 (385.2) |
0.022 |
| Fat intake (g/day) |
66.5 (19.7) |
63.5 (20.1) |
0.038 |
| Alcohol intake (g/day) |
8.6 (12.1) |
7.8 (11.2) |
0.179 |
| Oestradiol (pmol/l)b |
173.1 (341.3) |
136.9 (259.4) |
0.066 |
| Age at menarche (years) |
12.8 (1.6) |
13.0 (1.5) |
0.058 |
| Family history of breast cancer: yes |
23 (10%) |
74 (8%) |
0.216 |
| Breastfed children: yes |
155 (65%) |
617 (65%) |
0.865 |
| Number of children |
|||
| 0 |
38 (16%) |
117 (12%) |
0.174 |
| 1 |
26 (11%) |
134 (14%) |
|
| 2 |
103 (43%) |
398 (42%) |
|
| 3 |
57 (24%) |
218 (23%) |
|
| 4+ |
13 (6%) |
85 (9%) |
|
| Menopausal statusc |
|||
| Premenopausal |
28 (12%) |
123 (13%) |
0.569 |
| Perimenopausal |
15 (6%) |
51 (5%) |
|
| Postmenopausal 1 |
57 (24%) |
195 (21%) |
|
| Postmenopausal 2 |
137 (58%) |
583 (61%) |
|
| Menopausal hormone therapy use |
|||
| Current |
63 (27%) |
207 (22%) |
0.256 |
| Former |
30 (13%) |
118 (12%) |
|
| Never |
144 (61%) |
627 (66%) |
|
| Oral contraceptive use |
|||
| Current |
9 (4%) |
13 (1%) |
0.041 |
| Former |
98 (41%) |
419 (44%) |
|
| Never |
130 (55%) |
520 (55%) |
|
| Social class |
|||
| Professional/manager |
105 (45%) |
405 (42%) |
0.620 |
| Skilled nonmanual |
46 (20%) |
171 (18%) |
|
| Skilled manual |
51 (22%) |
197 (21%) |
|
| Semi-skilled/nonskilled |
20 (9%) |
112 (12%) |
|
| Missing/unclassified |
15 (4%) |
67 (7%) |
|
| Smoking status |
|||
| Current |
26 (11%) |
94 (10%) |
0.822 |
| Former |
70 (30%) |
297 (32%) |
|
| Never |
137 (59%) |
550 (59%) |
|
|
Data presented as mean ± standard deviation or n (column percentage). aP values obtained with a t test for continuous values and a chi-square test for categorical variables. bOestradiol data availability: serum phytoestrogens, 153 cases and 603 controls (51 cases and 185 controls among the oestrogen receptor-positive subgroup); urinary phytoestrogens, 141 cases and 543 controls (49 cases and 171 controls among the oestrogen receptor subgroup). cPerimenopausal, <1 year since last menstrual cycle; postmenopausal 1, 2 to 5 years since last menstrual cycle; postmenopausal 2, 5 years or more since last menstrual cycle. | |||
Ward et al. Breast Cancer Research 2008 10:R32 doi:10.1186/bcr1995 |
|||